biowatchdog You are FOS. Just make this up? Sure you did because most patients are cycled for 3 months on then off and rotated to another antibiotic.Effectiveness and lung deterioration in patients who's lives are cut short and critical,your argument is a red herring.The podhaler is a godsend. Arikace is a nebulizer.Both are good the problem is money enters and guess who will win that battle. Convenience and compliance make it choice #1.Europe already has.
why would the FDA think about NTM for the CF patient? The FDA knows what they are doing and knows Arikace is just another wannabe drug. Arikace wannabe as convient safe and effective but you first need a REFRIGERATOR!! The podhaler is cornering the market fast!
Hey gt Do not laugh.Revenues for CF in Europe will be a pittance. A Big fat ZERO in the US . Many people here though Arikace would make money in the US instead it wont even be sold here.
2015 to 2017 plus is a lot better then not being sold at all in the US. Arikace for CF denied in the USA
Novartis podhaler killing the competition Insmed is not much competition in Europe. NICE gave the podhaler FIRST TIER Status! Arikace will be third tier.
Arikace filing for the US No timeline. podhaler swallowing up the competition
PROOF! Lerrick Swann report Thank justarook04
******************TARGET fails, we model a $340MM worldwide market opportunity***************
for Arikace in CF that could create a ~$9 floor value for the stock .(83 million in worldwide sales by 2020
I say they are VERY optimistic that Arikace would get 85 Million,more like 50M! DO RESEARCH
ALL analysts agree.The podhaler will get the largest part of the US market at aprx 340M and the 360M market outside the US. ONLY THE FACTS Arikace will be a third tier entry with 75 to 100M TOPS. by 2025
too bad Insmed wont get a penny from the US cyc fib market.Novartis takes most 500Millionmarket
poor baby.Everybody is leaving because Insmed will get maybe 10% of that 400 M market..40M max! not 100M
Podhaler will get a min of 40% and more than likely HALF or 200Million.
less than 400M. The podhaler will get HALF and if inmsed gets their drug out there will split it with others.No more than 20% of the 400m or 80 million in 4 or 5 years. 320M or $7 a share. 11-14 a share est for NTM
Ritu Baral of Canaccord estimates.
You assume NTM will be approved in the next 3 years.Maybe maybe not. Arikace will not be approved in the US. See how poor the other DD is?
NICE has recommended dry powder for inhalation (Tobi Podhaler, Novartis) and they TURNED DOWN
Colistimethate sodium dry powder for inhalation (Colobreathe, Forest Laboratories UK).In socialized countries THEY DECIDE WHAT THE Universal system will cover.First tier is the podhaler. Safe AND Effective
Arikace doesnt stand a chance The podhaler is being sold now in the US. Arikace will not be sold in the US.
I am not doing DD for anyone here who doesnt do their own DD look at the superior Podhaler. Good Night
Bye Bye TOBI HELLO PODHALER! NOW - Not in two years! in 2 countries! Podhaler is #1 choice at European registries NOW and approved around the world - Get informed
You mean you do not know that they compared the SOLUTION from Novartis that is being replaced by the portable podhaler?-A Powder? in a device that is PORTABLE! and does not need refrigeration?
Arikace doesnt stand a chance. The podhaler is approved around the world and Arikce? 2 years to go and in Canada and Europe?
This was for our new good friend zake the flake...what a character..
GET INFORMED! BEFORE YOU MAKE A FOOL OF YOURSELF
Tobi Podhaler was more effective than placebo in treating P. aeruginosa infection in patients with cystic fibrosis. After four weeks of treatment, the patients taking Tobi Podhaler had an improvement in FEV1 of 13.2%, while patients taking placebo had a reduction in FEV1 of around 0.6%.